USA flag logo/image

An Official Website of the United States Government

DEVELOPMENT OF A QUANTITATIVE ANTIBODY BINDING KIT

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
7912
Program Year/Program:
1990 / SBIR
Agency Tracking Number:
7912
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
CARIBBEAN MICROPARTICLES CORP.
BOX 194344 SAN JUAN, PR 00919
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1990
Title: DEVELOPMENT OF A QUANTITATIVE ANTIBODY BINDING KIT
Agency: HHS
Contract: N/A
Award Amount: $251,296.00
 

Abstract:

THE DIAGNOSIS OF A VARIETY OF DISEASES (E.G., LEUKEMIA AND AIDS) CAN BE FACILITATED BY STUDYING THE VARIOUS SUB-POPULATIONS OF LEUKOCYTES IN THE BLOOD. ALTHOUGH MONOCLONAL ANTIBODIES HAVE BEEN USED SUCCESSFULLY TO QUALITATIVELY CHARACTERIZE MANY PATHOLOGICAL DISEASES, IT REMAINS EXTREMELY DIFFICULT TO QUANTITATE MONOCLONAL ANTIBODY BINDING SITES ON A PARTICULAR CELL TYPE. CHANGES IN THE NUMBER OF ANTIBODY-BINDING-SITES MAY SERVE AS AN INDEX TO THE STAGE OF A DISEASE, AS WELL AS, AN INDICATOR OF THE EFFECTIVENESS OF PARTICULAR MEDICAL TREATMENTS. THE AIM OF THIS PROPOSAL IS TO DEVELOP A CALIBRATION KIT FOR THECLINICAL FLOW CYTOMETER THAT WILL ALLOW AN EASY, DIRECT, AND INEXPENSIVE METHOD TO DETERMINE THE NUMBER OF MONOCLONALANTIBODY BINDING SITES PER CELL. THE METHOD WILL BE BASED ON A SET OF HIGHLY UNIFORM MICROBEADS, THAT BEHAVE AS "MODELCELLS" IN TERMS OF BOTH SIZE AND ANTIBODY BINDING BEHAVIOR. THESE MICROBEADS WILL BIND SPECIFIC AMOUNTS OF COMMERCIALLY AVAILABLE FLUORESCENT MONOCLONAL MOUSE IGG ANTIBODIES AND WILL SERVE AS THE STANDARDS TO CONSTRUCT CALIBRATION PLOTS OF INSTRUMENT RESPONSE AGAINST THE NUMBER OF FLUORESCENT ANTIBODIES USING A FLOW CYTOMETER. IN PHASE I OF THIS PROJECT, IT WILL BE DEMONSTRATED THAT THIS CALIBRATION PLOT MAY BE CONSTRUCTED AND USED TO DETERMINE THE NUMBER OF ANTIBODY BINDING SITES FOR PARTICULAR CELL POPULATIONS. PHASE II OF THE PROJECT WILL INVOLVE CLOSE COLLABORATION WITH CLINICIANS TO ASSESS THE CLINICAL APPLICABILITY OF THISKIT, AS WELL AS, ITS SCALE-UP MANUFACTURING AND COMMERCIALIZATION. IT IS EXPECTED THAT THIS NEW TECHNOLOGY WILL PROVIDE CLINICAL AND RESEARCH LABORATORIES WITH UNIQUE TOOL IN DIAGNOSIS, STUDY, AND TREATMENT OF CERTAIN DISORDERS.

Principal Investigator:


0

Business Contact:

Small Business Information at Submission:

Caribbean Microparticles Corp.
304 Muno-rivera Ave Suite #7 San Juan, PR 00901

EIN/Tax ID:
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No